Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer

Journal

• Clin Lung Cancer

  Clin Lung Cancer 6 (1), S20-S23, 2004